Innate Pharma announces first patient dosed in MATISSE trial

Innate Pharma (IPHA) announced the first patient was dosed in MATISSE, a Phase 2 multicenter single-arm study, sponsored by Innate Pharma, evaluating neoadjuvant and adjuvant treatment with IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with durvalumab and chemotherapy, in treatment-naive patients with resectable early stage non-small cell lung cancer. Innate is responsible for conducting the study and shares study costs with AstraZeneca (AZN). AstraZeneca supplies clinical trial drugs.